证券代码：300705 证券简称：九典制药 | --- | --- | --- | |----------------|--------------------------|-------------| | | 特定对象调研 □分析师会议 | | | 投资者关系活动 | □媒体采访 □业绩说明会 | | | 类别 | □新闻发布会 □路演活动 | | | | □现场参观 □其他 | | | 参与单位名称及 | | | | | | | | 人员姓名 | | | | 时间 2023 | 年 7 月 10 日下午 | 15:40-17:10 | 地点 公司会议室 上市公司接待人 副总经理兼董事会秘书：曾蕾 员姓名 证券事务代表：甘荣 主要采用解答投资者提问的方式进行，主要问题回复如下： 1、公司产品洛索洛芬钠凝胶贴膏中选广东联盟地区集采有 哪些地区已经开始供货了？如果其他省份进行集采价格会有 联动吗？ 回复：截止今年 6 月底，广东联盟地区集采已经执行的 地区有七个，分别是山西省、广东省、青海省、海南省、河 投资者关系活动 南省、新疆维吾尔自治区和新疆生产建设兵团。其他省份如 主要内容介绍 果进行集采会将已经集采过 ...

证券代码：300705 证券简称：九典制药 | --- | --- | --- | |----------------|-----------------------|-------------| | | | | | 投资者关系活动 | □媒体采访 □业绩说明会 | | | 类别 | □新闻发布会 □路演活动 | | | | □现场参观 □其他 | | | 参与单位名称及 | | | | | 长城证券 | | | 人员姓名 | | | | 时间 2023 | 年 7 月 5 日上午 | 10:00-11:30 | 地点 公司会议室 上市公司接待人 副总经理兼董事会秘书：曾蕾 员姓名 证券事务代表：甘荣 证券事务代表首先介绍了公司的基本情况。 接下来采用解答投资者提问的方式进行，主要问题回复如下： 1、酮洛芬凝胶贴膏、洛索洛芬钠凝胶贴膏有什么区别？ 回复：这两个产品适应症没有很大区别，但从药物的属 性来说，不同产品的疗效会存在一定的差异；不同产品的载 药量不同，作用时长也不一样。 投资者关系活动 主要内容介绍 2、公司目前已上市和在研的品种都是消炎镇痛类的，布局多 个同类型产品是因为什么原因？ 回复：公司在局部 ...

证券代码：300705 证券简称：九典制药 | --- | --- | --- | |----------------|--------------------------|-------------| | | 特定对象调研 □分析师会议 | | | 投资者关系活动 | □媒体采访 □业绩说明会 | | | 类别 | □新闻发布会 □路演活动 | | | | □现场参观 □其他 | | | 参与单位名称及 | | | | | 德邦证券 长城基金 | | | 人员姓名 | | | | 时间 2023 | 年 6 月 28 日下午 | 16:00-17:00 | 地点 公司会议室 上市公司接待人 副总经理兼董事会秘书：曾蕾 员姓名 证券事务代表：甘荣 主要采用解答投资者提问的方式进行，主要问题回复如下： 1、公司产品洛索洛芬钠凝胶贴膏中选广东联盟地区集采的 收入怎么样？ 回复：广东联盟地区集采执行事宜，各地区执行时间不 同，暂时无法统计。目前有部分地区已经开始执行采购。从 广东省、河南省的执行情况来看，是实现了较好的以价换量 投资者关系活动 的。广东联盟地区集采执行，将有利于扩大该产品在执行地 主要内容介绍 区销 ...

证券代码：300705 证券简称：九典制药 湖南九典制药股份有限公司 投资者关系活动记录表 | --- | --- | |----------------|------------------------------------------------------| | | 特定对象调研 □分析师会议 | | 投资者关系活动 | □媒体采访 □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | | | | 平安证券、招商基金、安信基金、汇添富基金、彤源投资、 | | 参与单位名称及 | | | | 易方达基金、华宝基金、财通基金、华能贵诚信托、华泰证 | | 人员姓名 | | | | 券高毅资产、海南益万家、华福证券、中海基金、盈峰资本 | | | 日上午 9:00-10:30 | | 时间 | 日下午 14:00-16:30 | | | 日下午 14:00-15:30 | | | | | | | | 上市公司接待人 | | | | | | 员姓名 | | | | | | | 主要采用解答投资者提问的方式进行，主要问题回复如下： | | | 、公司产品洛索洛芬钠凝胶贴膏中选广东联盟地区集采的 ...

Group 1: Financial Performance - The company expects a revenue and net profit growth of 25-35% in 2023, with net profit referring to the profit attributable to shareholders after deducting non-recurring gains and losses [3] - The R&D investment for 2023 is projected to be similar in proportion to revenue as in the previous year [3] Group 2: Product Development and Market Strategy - The company’s product, Loxoprofen Sodium Gel Patch, has been selected for the Guangdong Alliance regional procurement, which is expected to enhance market share and sales in executing regions [1] - The company is expanding sales channels for Loxoprofen Sodium Gel Patch, focusing on increasing coverage in large and medium-sized chain pharmacies [2] - Multiple new topical formulations are in clinical development, including Lidocaine Gel Patch and Indomethacin Gel Patch, with several others in preclinical research or project initiation stages [2] Group 3: Competitive Landscape - The market for external anti-inflammatory analgesics is currently limited, suggesting that Loxoprofen Sodium Gel Patch and Ketoprofen Gel Patch will complement each other in market promotion [2] Group 4: Key Products in Oral Formulations - Key oral formulations being promoted include Pantoprazole Sodium Enteric-coated Tablets, Loxoprofen Sodium Tablets, and several others that have been selected in national procurement batches [2]

证券代码：300705 证券简称：九典制药 湖南九典制药股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|--------------------------|-------------| | | 特定对象调研 □分析师会议 | | | 投资者关系活动 | □媒体采访 □业绩说明会 | | | 类别 | □新闻发布会 □路演活动 | | | | □现场参观 □其他 | | | 参与单位名称及 | | | | | 西部证券、招商基金 | | | 人员姓名 | | | | 时间 2023 | 年 5 月 23 日下午 | 15:30-17:00 | 地点 公司会议室 上市公司接待人 员姓名 副总经理兼董事会秘书：曾蕾 主要采用解答投资者提问的方式进行，主要问题回复如下： 1、公司产品洛索洛芬钠凝胶贴膏中选广东联盟地区集采的 收入怎么样？ 回复：广东联盟地区集采执行事宜，各地区执行时间不 同，暂时无法统计。目前有部分地区已经开始执行采购。目 前从广东省、河南省的执行情况来看，是实现了较好的以价 投资者关系活动 换量的。广东联盟地区集采执行，将有利于扩大该 ...

Group 1: Product Development and Market Position - The company believes that Ketoprofen gel patch and Loxoprofen sodium gel patch complement each other in the market, addressing unmet patient needs in the external anti-inflammatory analgesic drug market [1] - Ketoprofen gel patch has started sales, with bidding and listing completed in April 2023, and shipments have begun in certain provinces [2] - Loxoprofen sodium gel patch is primarily sold in hospitals, while the company is expanding sales channels to increase coverage in large and medium-sized chain pharmacies [2] Group 2: Clinical Research and Product Pipeline - Multiple external preparation products are currently undergoing clinical trials, including Lidocaine gel patch, Indomethacin gel patch, and others, with some already approved for clinical use [2] - The barriers to entry in the gel patch field include technical barriers related to drug release systems and lengthy administrative approval cycles [2] Group 3: Financial Performance and Goals - The company expects a year-on-year revenue and net profit growth of 25-35% for 2023, with net profit referring to the profit attributable to shareholders after deducting non-recurring gains and losses [2] - The total amount raised from the convertible bond issuance is expected to be no more than 360 million yuan, which will be used entirely for the development of a high-end formulation R&D industrial park for oral solid preparations [3]

Financial Performance - In Q1 2023, the company achieved operating revenue of 5.02 billion CNY, a year-on-year increase of 11.76% [1] - The net profit attributable to shareholders was 7,689.05 million CNY, reflecting a growth of 37.39% compared to the same period last year [1] - The net profit after deducting non-recurring gains and losses was 6,895.18 million CNY, up by 26.57% year-on-year [1] Product Sales Breakdown - Sales revenue from the main product, Losofen Sodium Gel, was 246 million CNY, a decrease of 5.64% from 261 million CNY in Q1 2022 [2] - Oral formulations generated sales revenue of 153 million CNY, showing a year-on-year growth of 26.85% [2] - Raw materials achieved sales revenue of 31.87 million CNY, with a year-on-year increase of 39.91% [2] - Pharmaceutical excipients reported sales revenue of 49.22 million CNY, up by 53.15% year-on-year [2] - Plant extracts and others generated sales revenue of 16.77 million CNY, reflecting a growth of 35.13% [2] Market Share and Product Structure - The proportion of Losofen in total revenue decreased from 58.13% to 49.08%, while oral formulations' share increased from 26.81% to 30.34% [2] - The overall gross margin for Q1 2023 was 74.91%, down from 79.1% in the previous year, attributed to changes in product structure [2] Clinical Development and Future Products - The company is actively developing multiple external use formulations, with several products in clinical trials [3] - The market for external patch agents was approximately 15 billion CNY in 2020, growing to about 18 billion CNY in 2021, with a growth rate of around 20% [3] - The company plans to invest in R&D, with expectations of approximately 10 new products being approved annually over the next 2-3 years [4]

Financial Performance - Total operating revenue for Q1 2023 reached ¥501,873,303.51, an increase of 11.6% compared to ¥449,062,914.36 in the same period last year[10] - The company's operating revenue for the current period was ¥501,873,303.51, representing an increase of 11.76% compared to the same period last year[11] - Net profit attributable to shareholders was ¥76,890,546.67, reflecting a growth of 37.39% year-over-year[11] - The net profit after deducting non-recurring gains and losses was ¥68,951,769.31, up by 26.57% from the previous year[11] - Basic and diluted earnings per share were both ¥0.22, marking a 29.41% increase year-over-year[11] - The company's operating profit for the current period was ¥85,861,272.00, an increase from ¥62,420,990.62 in the same period last year[20] Cash Flow - The net cash flow from operating activities reached ¥98,228,739.03, a significant increase of 5,414.59% compared to the same period last year[11] - The net cash flow from operating activities for the first quarter was ¥98,228,739.03, a significant increase of 5,414.59% compared to the previous period's net cash flow of -¥1,848,282.70[33] - The net cash flow from investing activities was -¥133,995,556.50, a decline of 258.52% compared to the previous period's net cash flow of ¥84,526,583.21, mainly due to increased long-term asset investments[33] - The net cash flow from financing activities was ¥47,040,354.71, a significant increase of 1,267.54% from the previous period's net cash flow of -¥4,029,029.69, primarily due to increased project loans[33] Assets and Liabilities - Total assets as of March 31, 2023, were ¥2,440,348,127.68, compared to ¥2,299,671,112.18 at the start of the year, reflecting a growth of 6.1%[9] - Total liabilities increased to ¥798,462,601.25 from ¥747,050,467.29, marking a rise of 6.5%[9] - The company's inventory as of Q1 2023 was ¥278,058,701.01, up from ¥241,039,257.35, indicating a growth of 15.3%[6] - Short-term borrowings rose to ¥81,394,373.89 from ¥71,568,322.23, an increase of 13.0%[9] - Total cash and cash equivalents at the end of the period amounted to ¥346,323,811.83, down from ¥455,046,435.86 in the previous period[31] Equity - The total equity attributable to shareholders reached ¥1,641,885,526.43, up from ¥1,552,620,644.89, reflecting a growth of 5.7%[9] - The total equity attributable to shareholders was ¥1,641,885,526.43, reflecting a growth of 5.75% compared to the previous year[11] Expenses - Research and development expenses increased to ¥42,597,978.69, compared to ¥34,289,853.06 in the previous year[20] - Operating costs increased to ¥125,938,556.98, reflecting a 34.17% rise compared to ¥93,861,775.81 in the previous period, primarily due to changes in revenue and product mix[33] - Management expenses surged by 78.47% to ¥19,361,866.30, up from ¥10,848,534.97, mainly due to increased equity incentive costs[33] - The company reported a 41.47% increase in income tax expenses to ¥8,983,704.23, up from ¥6,350,186.61, due to increased profits[33] Shareholder Information - The company reported a total of 3,154,206 shares held by individual shareholder Lü Jubao, representing 0.92% of total shares[36] - Major shareholders include Zhu Zhihong with 29,368,500 shares and a significant stake held by various investment funds[36] - The company has not disclosed any relationships or concerted actions among the top shareholders[36] Audit and Compliance - The first quarter report has not been audited, ensuring the financial data's integrity[46] - The company guarantees the accuracy and completeness of the quarterly report, with all board members assuming legal responsibility[42] - There are no adjustments or restatements required for previous accounting data[47] Government Subsidies - The company received government subsidies amounting to ¥9,038,368.49 during the current period[12] - The company received government subsidies, contributing to a 582.44% increase in other income to ¥9,223,493.74 from ¥1,351,554.00 in the previous period[33]

湖南九典制药股份有限公司 投资者关系活动记录表 证券代码：300705 证券简称：九典制药 编号：2023-11 投资者关系活动 类别 □特定对象调研 □分析师会议 □媒体采访 业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 参与单位名称及 人员姓名 九典制药 2022 年度业绩说明会采用网络远程方式进行，面向 全体投资者 时间 2023 年 4 月 18 日下午 15:00-17:00 地点 公司会议室 上市公司接待人 员姓名 总经理：郑霞辉 独立董事：阳秋林 副总经理兼董事会秘书：曾蕾 财务总监：熊英 保荐代表人：江伟 投资者关系活动 主要内容介绍 主要采用解答投资者提问的方式进行，问题回复如下： 1、公司年度经营情况？ 回复：尊敬的投资者，您好！2022 年公司以市场为中心， 积极推进营销模式升级，销售取得新突破。全年实现营业收 入 23.26 亿元，同比增长 42.92%；归属于上市公司股东的净 利润 2.7 亿元，同比增长 32.05%；归属于上市公司股东的扣 非后净利润 2.48 亿元，同比增长 37.80%。详细内容可参考公 司披露的 2022 年年度报告。感谢您对公司的关注！ 2、公 ...